Immunotherapeutic strategies targeting natural killer T cell responses in cancer

[1]  Ronald E. Bontrop,et al.  Immunogenetics , 2005, Genes and Immunity.

[2]  H. Bear,et al.  Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells , 2016, Journal of leukocyte biology.

[3]  Y. Mizoro,et al.  Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells , 2016, Stem cell reports.

[4]  C. Figdor,et al.  Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses , 2015, Oncoimmunology.

[5]  D. Zajonc,et al.  Recognition of Microbial Glycolipids by Natural Killer T Cells , 2015, Front. Immunol..

[6]  S. Ng,et al.  Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features , 2015, Stem cells international.

[7]  G. Besra,et al.  A Novel Glycolipid Antigen for NKT Cells That Preferentially Induces IFN-γ Production , 2015, The Journal of Immunology.

[8]  Vipin Kumar,et al.  Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer , 2015, Front. Immunol..

[9]  V. Cerundolo,et al.  The Regulatory Role of Invariant NKT Cells in Tumor Immunity , 2015, Cancer Immunology Research.

[10]  S. Strome,et al.  Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional. , 2015, Cytokine.

[11]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Hermans,et al.  An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment. , 2014, Blood.

[13]  D. Knight,et al.  A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy. , 2014, Nature chemical biology.

[14]  Daofeng Liu,et al.  Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. , 2014, Blood.

[15]  J. Berzofsky,et al.  NKT Cell Networks in the Regulation of Tumor Immunity , 2014, Front. Immunol..

[16]  Z. Gong,et al.  Transcriptomic analysis of a transgenic zebrafish hepatocellular carcinoma model reveals a prominent role of immune responses in tumour progression and regression , 2014, International journal of cancer.

[17]  B. Frisch,et al.  Targeted Delivery of α-Galactosylceramide to CD8α+ Dendritic Cells Optimizes Type I NKT Cell–Based Antitumor Responses , 2014, The Journal of Immunology.

[18]  J. Robert,et al.  A prominent role for invariant T cells in the amphibian Xenopus laevis tadpoles , 2014, Immunogenetics.

[19]  Bao-Ling Zhu,et al.  CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia , 2014, Oncology letters.

[20]  K. Tkaczuk,et al.  Development of a qPCR method to rapidly assess the function of NKT cells. , 2014, Journal of immunological methods.

[21]  J. Berzofsky,et al.  Liver sulfatide-reactive type II NKT cells recognize endogenous phospholipids , 2014, Journal of Immunotherapy for Cancer.

[22]  M. Frieman,et al.  NKT Cell Responses to B Cell Lymphoma , 2014, Medical sciences.

[23]  D. Margaritis,et al.  CD1d expression as a prognostic marker for chronic lymphocytic leukemia , 2014, Leukemia & lymphoma.

[24]  R. White,et al.  Zebrafish models of cancer: progress and future challenges , 2014, Current opinion in genetics & development.

[25]  Y. Okamoto,et al.  NKT Cells as an Ideal Anti-Tumor Immunotherapeutic , 2013, Front. Immunol..

[26]  H. Bear,et al.  Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells , 2013, Breast Cancer Research and Treatment.

[27]  S. van Calenbergh,et al.  Enhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor Protection , 2013, The Journal of Immunology.

[28]  J. Berzofsky,et al.  β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy , 2013, Clinical Cancer Research.

[29]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[30]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[31]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[32]  J. Berzofsky,et al.  Delicate balance among three types of T cells in concurrent regulation of tumor immunity. , 2013, Cancer research.

[33]  M. Dhodapkar,et al.  Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. , 2013, Blood.

[34]  M. Smyth,et al.  NKT cell adjuvants in therapeutic vaccines against hematological cancers , 2013, Oncoimmunology.

[35]  D. Speiser,et al.  CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses , 2012, Cancer Immunology, Immunotherapy.

[36]  Surajit Das,et al.  Immune system and immune responses in fish and their role in comparative immunity study: a model for higher organisms. , 2012, Immunology letters.

[37]  F. Berthold,et al.  Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hyun-Jeong Ko,et al.  The restoration of myeloid‐derived suppressor cells as functional antigen‐presenting cells by NKT cell help and all‐trans‐retinoic acid treatment , 2012, International journal of cancer.

[39]  Eugene S. Kim,et al.  IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. , 2012, The Journal of clinical investigation.

[40]  C. Heuser,et al.  Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. , 2012, Cancer research.

[41]  P. Dellabona,et al.  Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation , 2012, Oncoimmunology.

[42]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[43]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[44]  M. Kubo,et al.  Development and Function of Invariant Natural Killer T Cells Producing TH2- and TH17-Cytokines , 2012, PLoS biology.

[45]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[46]  M. Dhodapkar,et al.  Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. , 2011, Clinical immunology.

[47]  T. D. de Gruijl,et al.  Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. , 2011, Clinical immunology.

[48]  F. Locatelli,et al.  On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. , 2011, Clinical immunology.

[49]  Lisa L. Smith,et al.  Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse , 2011, The Journal of Immunology.

[50]  M. Nieda,et al.  Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of α-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells , 2011, Clinical Cancer Research.

[51]  S. van Calenbergh,et al.  Galactose‐modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis , 2011, The EMBO journal.

[52]  L. Sangalli,et al.  Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4− Subset Dynamics and Correlates with Remission State , 2011, The Journal of Immunology.

[53]  J. Berzofsky,et al.  Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity. , 2011, The Journal of clinical investigation.

[54]  D. Ho,et al.  Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant , 2010, Proceedings of the National Academy of Sciences.

[55]  O. Ohara,et al.  Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. , 2010, The Journal of clinical investigation.

[56]  D. Godfrey,et al.  Raising the NKT cell family , 2010, Nature Immunology.

[57]  M. Smyth,et al.  CD1d-Based Combination Therapy Eradicates Established Tumors in Mice1 , 2009, The Journal of Immunology.

[58]  R. Corvò,et al.  Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms , 2009, Haematologica.

[59]  S. Senju,et al.  Cytokine-Dependent Modification of IL-12p70 and IL-23 Balance in Dendritic Cells by Ligand Activation of Vα24 Invariant NKT Cells1 , 2009, The Journal of Immunology.

[60]  T. Shiratsuchi,et al.  Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. , 2009, Journal of immunological methods.

[61]  Yang Yang,et al.  Cutting Edge: CD28 Engagement Releases Antigen-Activated Invariant NKT Cells from the Inhibitory Effects of PD-11 , 2009, The Journal of Immunology.

[62]  S. Asgharzadeh,et al.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. , 2009, The Journal of clinical investigation.

[63]  Xiangming Li,et al.  Identification of C‐glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells , 2009, Immunology.

[64]  C. Liu,et al.  Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. , 2009, Vaccine.

[65]  S. Fujii,et al.  Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. , 2009, Blood.

[66]  J. Schneck,et al.  Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. , 2009, Journal of immunological methods.

[67]  I. Yoshino,et al.  A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer1 , 2009, The Journal of Immunology.

[68]  Hyun-Jeong Ko,et al.  Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine1 , 2009, The Journal of Immunology.

[69]  H. Bontkes,et al.  Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). , 2008, Cancer letters.

[70]  David H Adams,et al.  Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide , 2008, BMC Immunology.

[71]  M. Taniguchi,et al.  A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity , 2008, The Journal of experimental medicine.

[72]  Bruce L. Levine,et al.  Adoptive immunotherapy: good habits instilled at youth have long-term benefits , 2008, Immunologic research.

[73]  S. Jagannath,et al.  Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. , 2008, Blood.

[74]  M. Smyth,et al.  Diverse cytokine production by NKT cell subsets and identification of an IL-17–producing CD4−NK1.1− NKT cell population , 2008, Proceedings of the National Academy of Sciences.

[75]  G. Renukaradhya,et al.  Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. , 2008, Blood.

[76]  J. Berzofsky,et al.  Regulation of tumor immunity: the role of NKT cells , 2008, Expert opinion on biological therapy.

[77]  G. Besra,et al.  Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. , 2008, The Journal of clinical investigation.

[78]  John T. Harty,et al.  Shaping and reshaping CD8+ T-cell memory , 2008, Nature Reviews Immunology.

[79]  R. Steinman,et al.  Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity , 2007, Immunological reviews.

[80]  K. Sugamura,et al.  OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. , 2007, The Journal of clinical investigation.

[81]  R. Steinman,et al.  Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells , 2007, The Journal of experimental medicine.

[82]  Anneliese O. Speak,et al.  Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. , 2007, Immunity.

[83]  J. Berzofsky,et al.  Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis1 , 2007, The Journal of Immunology.

[84]  L. Kwak,et al.  An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. , 2007, Blood.

[85]  Chi‐Huey Wong,et al.  Identification of an IL-17–producing NK1.1neg iNKT cell population involved in airway neutrophilia , 2007, The Journal of experimental medicine.

[86]  Asha B. Pillai,et al.  Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation1 , 2007, The Journal of Immunology.

[87]  V. Cerundolo,et al.  Dendritic Cell Function Can Be Modulated through Cooperative Actions of TLR Ligands and Invariant NKT Cells1 , 2007, The Journal of Immunology.

[88]  Xiaofeng Jiang,et al.  Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. , 2006, Cancer research.

[89]  Y. Okamoto,et al.  A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[90]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[91]  L. Van Kaer,et al.  Inhibition of antitumor immunity by invariant natural killer T cells in a T‐cell lymphoma model in vivo , 2006, International journal of cancer.

[92]  P. Kufer,et al.  T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2006, Cancer Immunology, Immunotherapy.

[93]  S. Ogawa,et al.  CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells , 2006, Leukemia & lymphoma.

[94]  J. Berzofsky,et al.  A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance , 2005, The Journal of experimental medicine.

[95]  R. Steinman,et al.  Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells , 2005, The Journal of experimental medicine.

[96]  D. Pellicci,et al.  Differential antitumor immunity mediated by NKT cell subsets in vivo , 2005, The Journal of experimental medicine.

[97]  D. Pellicci,et al.  NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. , 2005, The Journal of clinical investigation.

[98]  A. Mori,et al.  Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas , 2005, Clinical Cancer Research.

[99]  A. Strasser,et al.  NKT Cell Stimulation with Glycolipid Antigen In Vivo: Costimulation-Dependent Expansion, Bim-Dependent Contraction, and Hyporesponsiveness to Further Antigenic Challenge1 , 2005, The Journal of Immunology.

[100]  H. Lyerly,et al.  Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. , 2005, International immunology.

[101]  C. Leemans,et al.  Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load , 2005 .

[102]  R. Steinman,et al.  Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients , 2005, The Journal of experimental medicine.

[103]  G. Cimino,et al.  CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis , 2005, Leukemia.

[104]  T. Iizasa,et al.  A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[105]  D. Ho,et al.  Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[106]  D. Purdie,et al.  Modulation of human Vα24+Vβ11+ NKT cells by age, malignancy and conventional anticancer therapies , 2004, British Journal of Cancer.

[107]  R. Steinman,et al.  The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation , 2004, The Journal of experimental medicine.

[108]  S. Groshen,et al.  Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2 , 2004, The Journal of experimental medicine.

[109]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[110]  T. Juji,et al.  Therapeutic activation of Vα24^+Vβ11^+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity , 2004 .

[111]  H. Young,et al.  Dissociation of NKT Stimulation, Cytokine Induction, and NK Activation In Vivo by the Use of Distinct TCR-Binding Ceramides1 , 2004, The Journal of Immunology.

[112]  M. Tsuji,et al.  Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide , 2003, The Journal of experimental medicine.

[113]  M. Taniguchi,et al.  The NKT cell system: bridging innate and acquired immunity , 2003, Nature Immunology.

[114]  A. Harris,et al.  NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells 1 , 2003, The Journal of Immunology.

[115]  Mitchell Kronenberg,et al.  Constitutive Cytokine mRNAs Mark Natural Killer (NK) and NK T Cells Poised for Rapid Effector Function , 2003, The Journal of experimental medicine.

[116]  S. Nimer,et al.  Severe and selective deficiency of interferon‐γ‐producing invariant natural killer T cells in patients with myelodysplastic syndromes , 2003, British journal of haematology.

[117]  H. Hirai,et al.  Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. , 2003, Cancer research.

[118]  R. Steinman,et al.  Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .

[119]  N. Segal,et al.  Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells , 2003, The Journal of experimental medicine.

[120]  K. Weinberg,et al.  Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells , 2003, Leukemia.

[121]  A. Mackensen,et al.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.

[122]  Yu-Jin Jung,et al.  In vitro differentiation of natural killer T cells from human cord blood CD34+ cells , 2003, British journal of haematology.

[123]  G. Giaccone,et al.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[124]  E. Baba,et al.  Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. , 2002, Clinical immunology.

[125]  E. Grant,et al.  CD1-dependent dendritic cell instruction , 2002, Nature Immunology.

[126]  Christopher H Contag,et al.  Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. , 2002, Cancer research.

[127]  J. Blum,et al.  Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[128]  G. Bubley,et al.  Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1 , 2001, The Journal of Immunology.

[129]  S. Seki,et al.  Mechanisms of the Antimetastatic Effect in the Liver and of the Hepatocyte Injury Induced by α-Galactosylceramide in Mice , 2001, The Journal of Immunology.

[130]  I. Saiki,et al.  Differential Regulation of Th1 and Th2 Functions of NKT Cells by CD28 and CD40 Costimulatory Pathways1 , 2001, The Journal of Immunology.

[131]  Y. Tanaka,et al.  TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. , 2001, Blood.

[132]  H. Macdonald,et al.  Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells , 2000, European journal of immunology.

[133]  B. Dörken,et al.  A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. , 2000, Blood.

[134]  Y. Koezuka,et al.  Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. , 1999, Journal of immunology.

[135]  T. Iizasa,et al.  Antitumor Cytotoxicity Mediated by Ligand-activated Human Vα24 NKT Cells , 1999 .

[136]  M. Taniguchi,et al.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. , 1999, Journal of immunology.

[137]  M. Kronenberg,et al.  CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution , 1998, The Journal of experimental medicine.

[138]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[139]  Hiroshi Sato,et al.  Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .

[140]  L. Zitvogel,et al.  Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. , 1995, Journal of immunology.

[141]  M. Zijlstra,et al.  Positive selection of invariant V alpha 14+ T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[142]  O. Lantz,et al.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans , 1994, The Journal of experimental medicine.

[143]  H. Koseki,et al.  Homogenous junctional sequence of the V14+ T-cell antigen receptor alpha chain expanded in unprimed mice. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[144]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[145]  J. Coligan,et al.  A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single Vβ gene family , 1987, Nature.

[146]  K. Shigemoto,et al.  Sequence and expression of transcripts of the T-cell antigen receptor alpha-chain gene in a functional, antigen-specific suppressor-T-cell hybridoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[147]  V. Raso,et al.  Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. , 1981, Cancer Research.

[148]  Takashi Nakamura,et al.  In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide-Loaded Liposomes and Interleukin-12. , 2016, Journal of pharmaceutical sciences.

[149]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[150]  J. Berzofsky,et al.  Regulation of tumor immunity: the role of NKT cells. , 2008, Expert opinion on biological therapy.

[151]  T. Iizasa,et al.  A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[152]  C. Leemans,et al.  Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. , 2005, International journal of cancer.

[153]  T. Juji,et al.  Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. , 2004, Blood.

[154]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[155]  T. Iizasa,et al.  Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. , 1999, Cancer research.

[156]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[157]  M. Fanger,et al.  Bispecific antibodies. , 1992, Critical reviews in immunology.

[158]  A. Fauci,et al.  Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. , 1988, Blood.